Literature DB >> 10178574

Burden of illness estimates for priority setting: a debate revisited.

V Wiseman1, G Mooney.   

Abstract

This paper returns to the debate in this journal about a decade ago on the value of cost of illness (COI) and burden of illness (BOI) estimates in priority setting. Concern is expressed that there has been a resurgence of interest in calculating and using BOI estimates in such priority setting. It is especially concerning that this interest seems to have support from both the World Bank and the World Health Organisation (WHO) (although perhaps less so recently from the latter). It is argued that in terms of priorities for health services, BOI calculations are irrelevant except possibly in the context of some (less than ideal) concept of need in support of equity. If the need basis for equity is set in terms of 'capacity to benefit', then BOI calculations become even less relevant. There is an argument for some research funding being prioritised in terms of BOI but only when it is genuinely the case that there is total ignorance, beyond the size of the problem, about a particular policy or disease area. Such a level of ignorance will happen very seldom and then some fairly approximate estimates of BOI will suffice. It is better to concentrate in priority setting on estimating the costs and benefits of marginal changes than devoting scarce analytical resources to superfluous estimates of BOI.

Entities:  

Mesh:

Year:  1998        PMID: 10178574     DOI: 10.1016/s0168-8510(98)00003-7

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  13 in total

1.  Resource allocation within Australian indigenous communities: a program for implementing vertical equity.

Authors:  V Wiseman; S Jan
Journal:  Health Care Anal       Date:  2000

2.  Guidelines for conducting and reporting economic evaluation of fall prevention strategies.

Authors:  J C Davis; M C Robertson; T Comans; P A Scuffham
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

Review 3.  Cost of lung cancer: a methodological review.

Authors:  Laurent Molinier; Christophe Combescure; Cristos Chouaïd; Jean-Pierre Daurès; Bruno Housset; Didier Fabre; Alain Grand; Alain Vergnenègre
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

5.  Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.

Authors:  Björn Stollenwerk; Thomas Welchowski; Matthias Vogl; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2015-02-04

6.  Sustained economic benefits of resistance training in community-dwelling senior women.

Authors:  Jennifer C Davis; Carlo A Marra; M Clare Robertson; Mehdi Najafzadeh; Teresa Liu-Ambrose
Journal:  J Am Geriatr Soc       Date:  2011-06-30       Impact factor: 5.562

7.  Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach.

Authors:  Bobby Tingstedt; Erik Andersson; Anton Flink; Kristian Bolin; Björn Lindgren; Roland Andersson
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

Review 8.  Cost-of-illness studies in diabetes mellitus.

Authors:  Lorraine Ettaro; Thomas J Songer; Ping Zhang; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Methodological considerations in cost of illness studies on Alzheimer disease.

Authors:  Nagede Costa; Helene Derumeaux; Thomas Rapp; Valérie Garnault; Laura Ferlicoq; Sophie Gillette; Sandrine Andrieu; Bruno Vellas; Michel Lamure; Alain Grand; Laurent Molinier
Journal:  Health Econ Rev       Date:  2012-09-11

10.  The cost of cochlear implantation: a review of methodological considerations.

Authors:  Costa Nadège; Garnault Valérie; Ferlicoq Laura; Derumeaux-Burel Hélène; Bongard Vanina; Deguine Olivier; Fraysse Bernard; Molinier Laurent
Journal:  Int J Otolaryngol       Date:  2011-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.